BACKGROUND: Allogeneic hematopoietic stem cell transplantation is associated with profound changes in levels of various cytokines. Emphasis has been placed on conditioning-associated mucosal damage and neutropenia and associated bacterial translocation as the initiating conditions predisposing to acute graft-versus-host disease. The post-transplant period is, however, also associated with increases in certain homeostatic cytokines. It is unclear how much the homeostatic drive to lymphocyte recovery and the production of cytokines from the engrafting donor immune system determine cytokine fluctuations in the peri- and immediate post-transplant period. The aim of this study was to examine the contributions of the conditioning regimen, donor engraftment, infections, and graft-versus-host disease to fluctuations in cytokines involved in homeostasis and inflammation. DESIGN AND METHODS: We examined the levels of 33 cytokines in relation to peri- and post-transplant events such as conditioning regimen, chimerism, and acute graft-versus-host disease in myeloablative, non-T cell-replete HLA-identical sibling donor stem cell transplantation for hematologic malignancies. RESULTS: We identified two cytokine storms. The first occurred following conditioning and reached peak levels when all the leukocytes were at their lowest concentrations. The second cytokine storm occurred concurrently with hematopoietic reconstitution and subsided with the achievement of full donor lymphocyte chimerism. CONCLUSIONS: Our results indicate that both recipient-related and donor-related factors contribute to the changes in cytokine levels in the recipient following allogeneic hematopoietic stem cell transplantation. The study reported here was performed using plasma samples drawn from patients enrolled in the ClinicalTrials.gov-registered trials NCT00467961 and NCT00378534.
BACKGROUND: Allogeneic hematopoietic stem cell transplantation is associated with profound changes in levels of various cytokines. Emphasis has been placed on conditioning-associated mucosal damage and neutropenia and associated bacterial translocation as the initiating conditions predisposing to acute graft-versus-host disease. The post-transplant period is, however, also associated with increases in certain homeostatic cytokines. It is unclear how much the homeostatic drive to lymphocyte recovery and the production of cytokines from the engrafting donor immune system determine cytokine fluctuations in the peri- and immediate post-transplant period. The aim of this study was to examine the contributions of the conditioning regimen, donor engraftment, infections, and graft-versus-host disease to fluctuations in cytokines involved in homeostasis and inflammation. DESIGN AND METHODS: We examined the levels of 33 cytokines in relation to peri- and post-transplant events such as conditioning regimen, chimerism, and acute graft-versus-host disease in myeloablative, non-T cell-replete HLA-identical sibling donor stem cell transplantation for hematologic malignancies. RESULTS: We identified two cytokine storms. The first occurred following conditioning and reached peak levels when all the leukocytes were at their lowest concentrations. The second cytokine storm occurred concurrently with hematopoietic reconstitution and subsided with the achievement of full donor lymphocyte chimerism. CONCLUSIONS: Our results indicate that both recipient-related and donor-related factors contribute to the changes in cytokine levels in the recipient following allogeneic hematopoietic stem cell transplantation. The study reported here was performed using plasma samples drawn from patients enrolled in the ClinicalTrials.gov-registered trials NCT00467961 and NCT00378534.
Authors: B de Saint-Vis; I Fugier-Vivier; C Massacrier; C Gaillard; B Vanbervliet; S Aït-Yahia; J Banchereau; Y J Liu; S Lebecque; C Caux Journal: J Immunol Date: 1998-02-15 Impact factor: 5.422
Authors: Zachariah A McIver; Jan J Melenhorst; Andrew Grim; Nicholas Naguib; Gerrit Weber; Vicki Fellowes; Hahn Khuu; David S Stroncek; Susan F Leitman; Minoo Battiwalla; A John Barrett Journal: Biol Blood Marrow Transplant Date: 2011-05-30 Impact factor: 5.742
Authors: M Imamura; S Hashino; H Kobayashi; S Kubayashi; S Hirano; T Minagawa; J Tanaka; Y Fujii; M Kobayashi; M Kasai Journal: Bone Marrow Transplant Date: 1994-06 Impact factor: 5.483
Authors: K R Cooke; G R Hill; J M Crawford; D Bungard; Y S Brinson; J Delmonte; J L Ferrara Journal: J Clin Invest Date: 1998-11-15 Impact factor: 14.808
Authors: Lindsay M Morton; Wael Saber; K Scott Baker; A John Barrett; Smita Bhatia; Eric A Engels; Shahinaz M Gadalla; David E Kleiner; Steven Pavletic; Linda J Burns Journal: Biol Blood Marrow Transplant Date: 2016-09-12 Impact factor: 5.742
Authors: Erik Boberg; Nadir Kadri; Jeanette Winterling; Lindsay C Davies; Andreas Björklund; Mussie Msghina; Ellen Iacobaeus; Katarina Le Blanc Journal: Haematologica Date: 2019-10-24 Impact factor: 9.941
Authors: Elizabeth O Hexner; Selina M Luger; Ran Reshef; Grace R Jeschke; James K Mangan; Noelle V Frey; Dale M Frank; Lee P Richman; Robert H Vonderheide; Nicole A Aqui; Misha Rosenbach; Yi Zhang; Anne Chew; Alison W Loren; Edward A Stadtmauer; Bruce L Levine; Carl H June; Stephen G Emerson; David L Porter Journal: Am J Hematol Date: 2016-04-04 Impact factor: 10.047
Authors: Barbara Bassani; Claudio Tripodo; Paola Portararo; Alessandro Gulino; Laura Botti; Claudia Chiodoni; Elena Jachetti; Niccolò Bolli; Marilena Ciciarello; Korinna Joehrens; Ioannis Anagnostopoulos; Il-Kang Na; Antonio Curti; Mario P Colombo; Sabina Sangaletti Journal: Front Immunol Date: 2021-05-18 Impact factor: 7.561
Authors: Angelique Biancotto; Abigail Wank; Shira Perl; Wendell Cook; Matthew J Olnes; Pradeep K Dagur; J Christopher Fuchs; Marc Langweiler; Ena Wang; J Philip McCoy Journal: PLoS One Date: 2013-12-12 Impact factor: 3.240
Authors: Mary D Thoma; Jennifer Glejf; Eapen Jacob; Tanya J Huneke; Lori J DeCook; Nicci D Johnson; Mrinal M Patnaik; Mark R Litzow; William J Hogan; Laura F Newell; Rekha Chandran; Luis F Porrata; Shernan G Holtan Journal: BMC Hematol Date: 2014-09-01